The article posted by Peace, Stapled Peptides Take a Torpedo from Genentech, is a fascinating read. If the assessment of stapled peptides by 'groups in Australia and at Genentech' is correct, Aileron Therapeutics may have some downhill sledding.
I wonder what Tomi Sawyer, CSO for Aileron, made of the comments in reply to the article. This one by ScientistSailor may have caused some heartburn;
"If any of you were still wondering why Genentech scientists poke at Roche...Roche paid $25MM for a bag of air that GNE already knew didn't work."
Still, colourful and unsubstantiated comments by anonymous posters can hardly be relied upon as investment advice particularly if they have a rather sharp axe to grind or grievance to lance.
The article posted by Peace, Stapled Peptides Take a Torpedo...
Add PYC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
9.8¢ |
Change
-0.007(6.67%) |
Mkt cap ! $489.9M | |||
| Open | High | Low | Value | Volume |
| 10.0¢ | 10.5¢ | 9.8¢ | $299.7K | 2.967M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 5102 | 9.8¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 9.9¢ | 102131 | 2 |
View Market Depth
| Last trade - 12.12pm 29/07/2024 (20 minute delay) ? |
| PYC (ASX) Chart |